AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34170647 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide 1 mg
Number of subjects: 1879
Study 34170647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 1879
Study 34170647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 1879
Study 32034480 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of CARM1
Number of subjects: 0
Study 32034480 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Con-H1299, Con-PC14)
Number of subjects: 0
Study 32034480 — intervention group
Group type: EXPERIMENTAL
Intervention: CARM1 supplementation in H1299 cells
Number of subjects: 0
Study 32034480 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of CARM1
Number of subjects: 0
Study 35930557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact-box styled message comparing risks of COVID-19 and vaccine
Number of subjects: 1075
Study 35930557 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline styled message describing the development process of COVID-19 mRNA vaccines
Number of subjects: 1075
Study 35930557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no message)
Number of subjects: 1075
Study 32426949 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein quality-optimized RUSF (75 kcal/kg/day for up to 12 weeks)
Number of subjects: 1737
Study 32426949 — intervention group
Group type: COMPARATOR
Intervention: Control RUSF (75 kcal/kg/day for up to 12 weeks)
Number of subjects: 1737
Study 32426949 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein quality-optimized RUSF
Number of subjects: 1737
Study 32426949 — intervention group
Group type: COMPARATOR
Intervention: Control RUSF
Number of subjects: 1737
Study 34930099 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages about COVID‐19 risk
Number of subjects: 1004
Study 34930099 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages about smoking risk
Number of subjects: 1004
Study 34930099 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined COVID‐19 and smoking risk messages
Number of subjects: 1004
Study 34930099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1004
Study 34930099 — intervention group
Group type: EXPERIMENTAL
Intervention: SPD presence
Number of subjects: 1004
Study 32228532 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based intervention and motivational interviewing
Number of subjects: 110
Study 32228532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110
Study 33849608 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly selinexor (100 mg), once weekly bortezomib (1.3 mg/m2), and 40 mg per week dexamethasone (XVd)
Number of subjects: 0
Study 33849608 — intervention group
Group type: COMPARATOR
Intervention: Standard twice weekly bortezomib and 80 mg per week dexamethasone (Vd)
Number of subjects: 0
Study 33322129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC) - told they would receive 6 mg/kg of caffeine but received a placebo
Number of subjects: 13
Study 33322129 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT) - no substance given
Number of subjects: 13
Study 36180567 — intervention group
Group type: COMPARATOR
Intervention: Single-layer modified Kugel mesh in the preperitoneal space
Number of subjects: 50
Study 36180567 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional onlay mesh in the inguinal canal with preperitoneal mesh placement
Number of subjects: 50
Study 36180567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1-layer and 2-layer)
Number of subjects: 50
Study 33449078 — intervention group
Group type: EXPERIMENTAL
Intervention: EUD (euhydrated arrival plus no fluid)
Number of subjects: 23
Study 33449078 — intervention group
Group type: EXPERIMENTAL
Intervention: EUR (euhydrated arrival plus fluid replacement)
Number of subjects: 23
Study 33449078 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD (hypohydrated arrival plus no fluid)
Number of subjects: 23
Study 32381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of clinical psoriatic samples
Number of subjects: 0
Study 32381429 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR‐fatty acids metabolism pathways
Number of subjects: 0
Study 32381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural‐hormone regulation pathways
Number of subjects: 0
Study 32381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian entrainment pathways
Number of subjects: 0
Study 32381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological immunofluorescence staining
Number of subjects: 0
Study 33941080 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg subcutaneous injection monthly with a loading dose of 240 mg
Number of subjects: 163
Study 35448950 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.2 mg/kg IV followed by etomidate 0.05 mg/kg IV (group E)
Number of subjects: 60
Study 35448950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg IV, then etomidate 0.1 mg/kg IV, followed by etomidate 0.05 mg/kg IV (group KE)
Number of subjects: 60
Study 35448950 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (group E)
Number of subjects: 60
Study 35448950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and etomidate (group KE)
Number of subjects: 60
Study 34642756 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup (1CB, 180 g) of canned beans
Number of subjects: 73
Study 34642756 — intervention group
Group type: EXPERIMENTAL
Intervention: ½ cup (½CB, 90 g) of canned beans
Number of subjects: 73
Study 34642756 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR) control
Number of subjects: 73
Study 32800653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure Plus with Zenpep (75,000 USP lipase units)
Number of subjects: 17
Study 32800653 — intervention group
Group type: COMPARATOR
Intervention: Ensure Plus alone
Number of subjects: 17
Study 36141875 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching
Number of subjects: 18
Study 36141875 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 18
Study 33845888 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy without dural tenting sutures
Number of subjects: 0
Study 33845888 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy with dural tenting sutures
Number of subjects: 0
Study 32723679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fosbretabulin
Number of subjects: 107
Study 32723679 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 107
Study 36069189 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational mapping system using 12-lead ECG data
Number of subjects: 225
Study 34982716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Link intervention (automated twice-weekly SMS and voice messages)
Number of subjects: 1118
Study 34982716 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing standard care including free HIV and STI counseling and testing)
Number of subjects: 1118
Study 32700396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 50
Study 32700396 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/d
Number of subjects: 50
Study 35712855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 61
Study 35712855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime restriction therapy
Number of subjects: 61
Study 35712855 — intervention group
Group type: COMPARATOR
Intervention: Control condition (time in bed regularisation)
Number of subjects: 61
Study 33939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Antischistosomal mass drug administration (MDA) with praziquantel
Number of subjects: 200000
Study 32522251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w
Number of subjects: 2108
Study 32522251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150/200 mg q2w + csDMARDs
Number of subjects: 2108
Study 32522251 — intervention group
Group type: COMPARATOR
Intervention: Placebo + csDMARDs
Number of subjects: 2108
Study 32522251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 2108
Study 33932949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction (Group II: 32 patients)
Number of subjects: 57
Study 33932949 — intervention group
Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (Group I: 25 patients)
Number of subjects: 57
Study 33932949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction
Number of subjects: 57
Study 34433305 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based thrombolysis with alteplase
Number of subjects: 503
Study 34433305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 32973176 — intervention group
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA) 45 mg/m2 orally, days 1–15/cycle in combination with gemcitabine-nab-paclitaxel chemotherapy
Number of subjects: 27
Study 32973176 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-nab-paclitaxel chemotherapy
Number of subjects: 27
Study 32973176 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 27
Study 36056421 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib fixation and standard pain medication
Number of subjects: 102
Study 36056421 — intervention group
Group type: COMPARATOR
Intervention: Standard pain medication alone
Number of subjects: 102
Study 34749675 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant Engagement Activities (PEAs)
Number of subjects: 2629
Study 34749675 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at multiple PEAs
Number of subjects: 2629
Study 35144700 — intervention group
Group type: COMPARATOR
Intervention: 4‐year EI
Number of subjects: 360
Study 35144700 — intervention group
Group type: COMPARATOR
Intervention: 2‐year EI
Number of subjects: 360
Study 35607896 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) training
Number of subjects: 68
Study 35607896 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (pro-environmental training)
Number of subjects: 68
Study 32170451 — intervention group
Group type: EXPERIMENTAL
Intervention: cONS (2.4 kcal/ml, 125 ml)
Number of subjects: 51
Study 32170451 — intervention group
Group type: COMPARATOR
Intervention: sONS (1.5 kcal/ml, 200 ml)
Number of subjects: 51
Study 36403158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus gentamicin (arm B)
Number of subjects: 7617
Study 36403158 — intervention group
Group type: COMPARATOR
Intervention: Procaine benzylpenicillin and gentamicin (arm C)
Number of subjects: 7617
Study 33692429 — intervention group
Group type: EXPERIMENTAL
Intervention: High salinity treatment (300-500 mM NaCl)
Number of subjects: 0
Study 33692429 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly selected genes of important pathways
Number of subjects: 0
Study 32237331 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqin Qingre Chubi Capsules (HQC)
Number of subjects: 58
Study 32237331 — intervention group
Group type: COMPARATOR
Intervention: Salazosulfapyridine (SASP)
Number of subjects: 58
Study 32237331 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy people)
Number of subjects: 58
Study 36187125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with meibomian gland expression (MGX)
Number of subjects: 13
Study 36187125 — intervention group
Group type: COMPARATOR
Intervention: Instant warm compresses combined with MGX (physiotherapy group)
Number of subjects: 13
Study 33958525 — intervention group
Group type: EXPERIMENTAL
Intervention: Radicular cysts (RCs)
Number of subjects: 60
Study 33958525 — intervention group
Group type: COMPARATOR
Intervention: Residual radicular cysts
Number of subjects: 60
Study 33958525 — intervention group
Group type: COMPARATOR
Intervention: Intense inflammatory infiltrate
Number of subjects: 60
Study 32794023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (15%) for 14 days
Number of subjects: 10
Study 35486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia Training (IHT)
Number of subjects: 20
Study 35486840 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 32841475 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mm NaCl
Number of subjects: 5
Study 32841475 — intervention group
Group type: EXPERIMENTAL
Intervention: >50 mm NaCl
Number of subjects: 5
Study 35148736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA 20 mg/kg preoperatively, followed by 10 mg/kg at 3 and 6 hours postoperatively, and gauze soaked with TXA for 10 minutes before incision closure
Number of subjects: 49
Study 33487528 — intervention group
Group type: COMPARATOR
Intervention: Screening only (Control)
Number of subjects: 2571
Study 33487528 — intervention group
Group type: EXPERIMENTAL
Intervention: PFBA (Personalised Feedback and Brief Advice)
Number of subjects: 2571
Study 33487528 — intervention group
Group type: EXPERIMENTAL
Intervention: PFBA plus eBI (electronic brief intervention)
Number of subjects: 2571
Study 35608683 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Clinpro Sealant, 3 M ESPE, MN, USA) plus adhesive (Single Bond Universal, 3 M ESPE, MN, USA)
Number of subjects: 54
Study 35608683 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin (Filtek Flow Z350XT, 3 M ESPE, MN, USA) plus adhesive (Single Bond Universal, 3 M ESPE, MN, USA)
Number of subjects: 54
Study 35608683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no repair treatment)
Number of subjects: 54
Study 33504932 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution theory-based online video intervention
Number of subjects: 147
Study 33504932 — intervention group
Group type: COMPARATOR
Intervention: Positive control video
Number of subjects: 147
Study 33504932 — intervention group
Group type: COMPARATOR
Intervention: Negative control video
Number of subjects: 147
Study 33087584 — intervention group
Group type: COMPARATOR
Intervention: Standard conscious sedation (SCS) including opiates and/or benzodiazepines pre-ICA
Number of subjects: 72
Study 33087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Music plus opiates and/or benzodiazepines as needed
Number of subjects: 72
Study 35150651 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 0
Study 35150651 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 34074879 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy
Number of subjects: 0
Study 34074879 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0
Study 34074879 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0
Study 34074879 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV cell-mediated immune assays
Number of subjects: 0
Study 34853185 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of stage‐of‐change‐based physical activity education and counseling plus written educational material
Number of subjects: 35
Study 34853185 — intervention group
Group type: COMPARATOR
Intervention: Written educational material alone
Number of subjects: 35
Study 35988568 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose betamethasone (11·4 mg)
Number of subjects: 3141
Study 35988568 — intervention group
Group type: COMPARATOR
Intervention: Full-dose betamethasone (11·4 mg)
Number of subjects: 3141
Study 33369763 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 88
Study 33369763 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (SF)
Number of subjects: 88
Study 33369763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors with strong expression of EpCAM
Number of subjects: 88
Study 33369763 — intervention group
Group type: COMPARATOR
Intervention: Tumors without strong expression of EpCAM
Number of subjects: 88
Study 33369763 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and p16 status
Number of subjects: 88
Study 32950115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led physical activity intervention (outdoor group walking, 5 days a week for 12 weeks, 40 minutes each session)
Number of subjects: 12
Study 32950115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 34505395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outcome data analysis
Number of subjects: 0
Study 34505395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outcome data as a surrogate
Number of subjects: 0
Study 34022073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulations containing cannabidiol (CBD) and palmitoylethanolamide (PEA)
Number of subjects: 0
Study 34022073 — intervention group
Group type: COMPARATOR
Intervention: Hemp seed oil product
Number of subjects: 0
Study 34022073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid products (CBD, PEA, and hemp seed oil formulations)
Number of subjects: 0
Study 36184061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 115
Study 36184061 — intervention group
Group type: COMPARATOR
Intervention: ILR monitoring
Number of subjects: 115
Study 33260376 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT/HOMO/VITE (citicoline 500 mg, homotaurine 50 mg, vitamin E 12 mg) in addition to current topical therapy for 4 months.
Number of subjects: 109
Study 33260376 — intervention group
Group type: COMPARATOR
Intervention: Current topical therapy alone for 4 months (after CIT/HOMO/VITE treatment).
Number of subjects: 109
Study 33260376 — intervention group
Group type: EXPERIMENTAL
Intervention: Current topical therapy for 4 months followed by CIT/HOMO/VITE for 4 months.
Number of subjects: 109
Study 33260376 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT/HOMO/VITE in addition to current topical therapy for 4 months followed by topical therapy alone for 4 months.
Number of subjects: 109
Study 34737786 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention combined with conventional medication
Number of subjects: 0
Study 34737786 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication alone
Number of subjects: 0
Study 32371199 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring data (pre-ablation)
Number of subjects: 346
Study 32371199 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment (pre-ablation)
Number of subjects: 346
Study 35876757 — intervention group
Group type: COMPARATOR
Intervention: Standard Malleable Stylet (SMS)
Number of subjects: 51
Study 35876757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Rigid Stylet (PRS)
Number of subjects: 51
Study 35876757 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube Introducer (TTI)
Number of subjects: 51
Study 34433441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory care planning (ACP) intervention
Number of subjects: 16
Study 33253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive treatment (n = 20)
Number of subjects: 40
Study 33253237 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive control (n = 20)
Number of subjects: 40
Study 35377244 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of undenatured collagen daily for 24 weeks
Number of subjects: 96
Study 35377244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 96
Study 32299108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Foley balloon and misoprostol (PGE1)
Number of subjects: 236
Study 32299108 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (PGE1) alone
Number of subjects: 236
Study 36182743 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) applied to fathers and newborns
Number of subjects: 60
Study 36182743 — intervention group
Group type: COMPARATOR
Intervention: No kangaroo care (control group)
Number of subjects: 60
Study 33689635 — intervention group
Group type: EXPERIMENTAL
Intervention: Near optical correction containing base-in prism
Number of subjects: 64
Study 33689635 — intervention group
Group type: COMPARATOR
Intervention: Near optical correction (placebo)
Number of subjects: 64
Study 32414347 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed physical activity program with motivational interviewing (MI) for 12 weeks
Number of subjects: 64
Study 32414347 — intervention group
Group type: COMPARATOR
Intervention: Self-directed physical activity program without motivational interviewing (delayed intervention)
Number of subjects: 64
Study 35575069 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐MOPs
Number of subjects: 33
Study 35575069 — intervention group
Group type: COMPARATOR
Intervention: non‐MI‐MOPs
Number of subjects: 33
Study 33721201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stakes assessment (assessment would affect the resident’s progress)
Number of subjects: 158
Study 33721201 — intervention group
Group type: COMPARATOR
Intervention: Low-stakes assessment (assessment would not affect the resident’s progress)
Number of subjects: 158
Study 32640196 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal telemonitoring for 6 months
Number of subjects: 206
Study 32640196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 206
Study 35764027 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp Reinforced Education (WRE)
Number of subjects: 685
Study 35764027 — intervention group
Group type: COMPARATOR
Intervention: No Reinforced Education (NRE)
Number of subjects: 685
Study 32907521 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (in-hospital medication evaluation, drug reorganization, medical monitoring, and advice via telemedicine)
Number of subjects: 120
Study 32907521 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 120
Study 32907521 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 120
Study 32907521 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 32524948 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day course)
Number of subjects: 0
Study 32524948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0